RCTs: Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis.
30 May, 2022 | 11:12h | UTCUpadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials – The Lancet (link to abstract – $ for full-text)